BMS launches dual immunotherapy for metastatic melanoma
Bristol Myers Squibb has launched RELOPDUO in India, a dual immunotherapy treatment for metastatic melanoma. The drug combines nivolumab and relatlimab to target two immune checkpoints, offering improved survival rates for patients.
Why it matters
This represents a significant advancement in cancer treatment accessibility for patients in India suffering from advanced melanoma.
Bristol Myers Squibb (BMS) has announced the launch of RELOPDUO, a fixed-dose combination of nivolumab and relatlimab) in India following approval from the Central Drugs Standard Control Organisation (CDSCO).
The company said the therapy is India’s first LAG-3-based dual immunotherapy and is indicated for adults and children aged 12 years and above with unresectable or metastatic melanoma. RELOPDUO combines the PD-1 inhibitor nivolumab with the LAG-3 inhibitor relatlimab to target two immune checkpoints involved in the body’s immune response against cancer.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in